Technical Analysis for ACOR - Acorda Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 29.45 -1.51% -0.45
ACOR closed down 1.51 percent on Friday, June 22, 2018, on 1.4 times normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical ACOR trend table...

Date Alert Name Type % Chg
Jun 22 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Jun 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jun 22 Wide Bands Range Expansion 0.00%
Jun 22 Down 3 Days in a Row Weakness 0.00%
Jun 22 Down 4 Days in a Row Weakness 0.00%
Jun 22 Down 5 Days in a Row Weakness 0.00%
Jun 21 MACD Bearish Signal Line Cross Bearish -1.51%
Jun 21 1,2,3 Pullback Bullish Bullish Swing Setup -1.51%
Jun 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.51%
Jun 21 Multiple of Ten Bearish Other -1.51%

Older signals for ACOR ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Is ACOR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 36.35
52 Week Low 16.55
Average Volume 577,625
200-Day Moving Average 24.5066
50-Day Moving Average 25.653
20-Day Moving Average 28.7875
10-Day Moving Average 30.965
Average True Range 1.2952
ADX 47.19
+DI 32.3
-DI 16.92
Chandelier Exit (Long, 3 ATRs ) 32.4644
Chandelier Exit (Short, 3 ATRs ) 26.6856
Upper Bollinger Band 33.8317
Lower Bollinger Band 23.7433
Percent B (%b) 0.57
BandWidth 35.044377
MACD Line 1.5308
MACD Signal Line 1.6638
MACD Histogram -0.1329
Fundamentals Value
Market Cap 1.37 Billion
Num Shares 46.6 Million
EPS -0.94
Price-to-Earnings (P/E) Ratio -31.33
Price-to-Sales 2.27
Price-to-Book 1.76
PEG Ratio 0.51
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.48
Resistance 3 (R3) 31.42 30.68 31.14
Resistance 2 (R2) 30.68 30.17 30.71 31.02
Resistance 1 (R1) 30.07 29.85 29.70 30.13 30.91
Pivot Point 29.33 29.33 29.15 29.36 29.33
Support 1 (S1) 28.72 28.82 28.35 28.78 27.99
Support 2 (S2) 27.98 28.50 28.01 27.88
Support 3 (S3) 27.37 27.98 27.76
Support 4 (S4) 27.43